All In Biotech

Drug Trial Radar · NCT05607498

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Last checked: Nov 19, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Mar 1, 2023

Primary completion

Oct 31, 2025

Study completion Mar 31, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.

Conditions

  • Advanced/Metastatic Solid Tumors
  • Relapse/Refractory Lymphoma

Interventions

  • EMB07Drug

    EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events as assessed by CTCAE V5.0.Time frame: Screening up to 30 days after the last dose.
  2. Incidence of serious adverse events (SAE).Time frame: Screening up to 30 days after the last dose, or beyond 30 days if SAE is confirmed to be treatment related.
  3. Incidence of dose interruptions.Time frame: Screening up to 30 days after the last dose.
  4. Dose intensity.Time frame: Screening up to 30 days after the last dose.
  5. The incidence of DLTs during the first cycle of treatment.Time frame: First infusion to the end of cycle 1. (each cycle is 28 days).

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Peninsula and South Eastern Haematology and Oncology Group

    Frankston, Victoria, Australia · Recruiting

  • One Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • Affiliated Hospital of Hebei University

    Baoding, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China · Recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, China · Recruiting

  • The Affiliated Tumour Hospital of Harbin Medical University

    Harbin, China · Recruiting

  • Shandong Cancer Hospital

    Shandong, China · Recruiting

  • Tianjin Medical University Cancer Institue & Hospital

    Tianjin, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.